First-line pembrolizumab for patients with early relapsing urothelial carcinoma after perioperative chemotherapy: a retrospective analysis of bladder cancer and upper urinary tract cancer

被引:0
作者
Nobutaka Nishimura
Makito Miyake
Takuto Shimizu
Toshihiko Matsubara
Tatsuki Miyamoto
Keichi Sakamoto
Atsushi Yamada
Yoshihiro Matsumoto
Motokiyo Yoshikawa
Kazuki Ichikawa
Chihiro Omori
Fumisato Maesaka
Yuki Oda
Keisuke Kiba
Atsushi Tomioka
Yukinari Hosokawa
Masahiro Tanaka
Takeshi Otani
Kiyohide Fujimoto
机构
[1] Nara Medical University,Department of Urology
[2] Gyoumeikan Hospital,Department of Urology
[3] Hoshigaoka Medical Center,Department of Urology
[4] Yamato Takada Municipal Hospital,Department of Urology
[5] Kouseikai Takai Hospital,Department of Urology
[6] Nara Prefecture General Medical Center,Department of Urology
[7] Nara City Hospital,Department of Urology
[8] Nara Prefecture Seiwa Medical Center,Department of Urology
[9] Kindai University Nara Hospital,Department of Urology
[10] Saiseikai Chuwa Hospital,Department of Urology
[11] Tane General Hospital,Department of Urology
[12] Gokeikai Osaka Kaisei Hospital,Department of Urology
[13] Matsusaka Chuo General Hospital,Department of Urology
来源
International Journal of Clinical Oncology | 2022年 / 27卷
关键词
First-line pembrolizumab; Early relapsing disease; Platinum-based perioperative chemotherapy; Radical surgery; Urothelial cancer;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1733 / 1741
页数:8
相关论文
共 67 条
[1]  
Grossman HB(2003)Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 859-866
[2]  
Natale RB(2014)Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan clinical oncology group study JCOG0209 Ann Oncol 25 1192-1198
[3]  
Tangen CM(2018)Effectiveness of adjuvant chemotherapy after radical cystectomy for locally advanced and/or pelvic lymph node-positive muscle-invasive urothelial carcinoma of the bladder: a propensity score-weighted competing risks analysis Eur Urol Focus 4 252-259
[4]  
Kitamura H(2018)Adjuvant chemotherapy vs observation for patients with adverse pathologic features at radical cystectomy previously treated with neoadjuvant chemotherapy JAMA Oncol 4 225-229
[5]  
Tsukamoto T(2021)Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy Eur Urol 79 635-654
[6]  
Shibata T(2017)Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review World J Urol 35 1401-1407
[7]  
Vetterlein MW(2000)Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 3068-3077
[8]  
Seisen T(2012)Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup Study 30987 J Clin Oncol 30 1107-1113
[9]  
May M(2017)Pembrolizumab as second-line therapy for advanced urothelial carcinoma N Engl J Med 376 1015-1026
[10]  
Seisen T(2021)Response to pembrolizumab after dose-reduced cisplatin plus gemcitabine chemotherapy is inferior to that after carboplatin plus gemcitabine chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma Clin Genitourin Cancer 28 899-905